Trading-BUY für VITX (923144).. akt. -70%.. Chance auf Rebound.. - 500 Beiträge pro Seite
eröffnet am 18.11.03 17:49:20 von
neuester Beitrag 03.02.04 19:03:41 von
neuester Beitrag 03.02.04 19:03:41 von
Beiträge: 36
ID: 797.163
ID: 797.163
Aufrufe heute: 0
Gesamt: 1.469
Gesamt: 1.469
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| 01.04.24, 10:52 | 259 | |
| gestern 21:20 | 242 | |
| heute 01:24 | 220 | |
| 22.06.20, 20:50 | 172 | |
| gestern 19:37 | 140 | |
| heute 00:34 | 126 | |
| gestern 22:23 | 111 | |
| gestern 23:03 | 105 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 17.737,36 | -0,56 | 198 | |||
| 2. | 2. | 147,05 | -1,92 | 95 | |||
| 3. | 7. | 6,6320 | -1,43 | 70 | |||
| 4. | 5. | 0,1810 | -1,90 | 51 | |||
| 5. | Neu! | 713,65 | -23,14 | 46 | |||
| 6. | 8. | 3,7700 | +0,80 | 45 | |||
| 7. | 17. | 7,2900 | -0,21 | 43 | |||
| 8. | 4. | 2.390,60 | 0,00 | 41 |
Feedback
VITX - 923144
akt: 0,58€
Trading-BUY in der Hoffnung auf Rebound!
1. KZ: 0,7€
akt: 0,58€
Trading-BUY in der Hoffnung auf Rebound!
1. KZ: 0,7€
usa 0,71$ 
0,74$
0,63€
Hallo tdwzb,
was ist der Grund für den Absturz??
was ist der Grund für den Absturz??
Trading Spotlight
Vitex halts enrollment in product`s late trial
Reuters
Monday November 17, 8:29 PM EST
NEW YORK, Nov 17 (Reuters) - V.I. Technologies Inc. (VITX), a biotechnology company, said on Monday it halted patient enrollment in its Phase III trial of the Inactine Pathogen Reduction System after a panel found immune system responses to red blood cells that were treated.
No serious adverse events were found in the study of a system that intends to eliminate pathogens in the blood supply, the Watertown, Massachusetts-based company said. New patients will not be enrolled in the study until an assessment is completed, the company said.
V.I. Technologies, which is also known as Vitex, said it intends to enroll patients in a surgical study of Inactine for cardiac surgery patients requiring acute transfusion support.
Reuters
Monday November 17, 8:29 PM EST
NEW YORK, Nov 17 (Reuters) - V.I. Technologies Inc. (VITX), a biotechnology company, said on Monday it halted patient enrollment in its Phase III trial of the Inactine Pathogen Reduction System after a panel found immune system responses to red blood cells that were treated.
No serious adverse events were found in the study of a system that intends to eliminate pathogens in the blood supply, the Watertown, Massachusetts-based company said. New patients will not be enrolled in the study until an assessment is completed, the company said.
V.I. Technologies, which is also known as Vitex, said it intends to enroll patients in a surgical study of Inactine for cardiac surgery patients requiring acute transfusion support.
#5
der Grund für den Absturz
der ganz normale Wahnsinn
der Grund für den Absturz
der ganz normale Wahnsinn
Danke!
@7: Hatte ich glatt übersehen - da Close < 1 USD
Greetinxx Heinerle2
Greetinxx Heinerle2
Geht wieder nach oben!
KZ-> 0,8-0,9 Euro!
KZ-> 0,8-0,9 Euro!
Gap könnte geschlossen werden, ich denke der Markt hat hier etwas überreagiert!
Strong buy bis 1?
Mfg M.o.M.
Strong buy bis 1?
Mfg M.o.M.
island 1. kurs 0,85$ -> 0,71€
usa taxt auch mit 0,84!
www.island.com = USA 
sorry!
sollte genauer lesen!
sollte genauer lesen!
Die gehen heute noch durch die Decke 
VITX -- V.I. Technologies, Inc.
Com (1 Cent)
Company News and Press Releases From Other Sources:
TheSUBWAY.com Announces Its Morning Stock Focus List for Thursday, November 20, 2003: RDVN, VITX, EBAY, USXP
WESTON, Fla., Nov 20, 2003 (PRIMEZONE via COMTEX) -- TheSUBWAY.com announces Renegade Ventures Corporation (OTCBB:RDVN) to its Stock Focus List. RDVN is new to TheSUBWAY.com, and we expect great things from this stock! Watch this company; it has announced great news, and we think it is due to make a move in the near term! Other stocks highlighted include:
V.I.Technologies Inc.(Nasdaq:VITX):Market Perform,
eBay Inc. (Nasdaq:EBAY): Market Underperform,
Universal Express Inc. (OTCBB:USXP): Market Perform,
WHAT THESE RATINGS MEAN:
TheSUBWAY.com ranks stocks from time to time utilizing both fundamental and technical analysis in comparison to the S&P 500 over the short term. These ratings reflect the opinion of TheSUBWAY.com.
ABOUT TheSUBWAY.com:
TheSUBWAY.com, a leader in corporate communications and finance, provides all investors with a wide-ranging set of financial tools, including original stock market commentary, stock quotes, interactive charts, portfolio watch, live chat and message boards, etc., plus the latest news, press releases, investment opinions, and research reports for all companies highlighted on the site. For more daily commentary, go to http://www.thesubway.com/sub_comm.asp." target="_blank" rel="nofollow ugc noopener">http://www.thesubway.com/sub_comm.asp.
All material herein was prepared by Capital Research Group, Inc. (CRG) based upon information believed to be reliable. The information contained herein is not guaranteed by CRG to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. CRG is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.thesubway.com or mentioned herein. CRG has been compensated by third party shareholders or with cash from the company on behalf of one or more of the companies mentioned in this opinion. (CRG has been compensated twenty thousand dollars for rdvn) CRG intends to sell its shares. CRG has sold approximately zero shares to date. CRG may sell its shares for less than the target price given in this opinion. CRG`s affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. CRG will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
SOURCE: Capital Research Group, Inc
INVESTMENT OPINION
VITX -- V.I. Technologies, Inc.
Com (1 Cent)
Company News and Press Releases From Other Sources:
TheSUBWAY.com Announces Its Morning Stock Focus List for Thursday, November 20, 2003: RDVN, VITX, EBAY, USXP
WESTON, Fla., Nov 20, 2003 (PRIMEZONE via COMTEX) -- TheSUBWAY.com announces Renegade Ventures Corporation (OTCBB:RDVN) to its Stock Focus List. RDVN is new to TheSUBWAY.com, and we expect great things from this stock! Watch this company; it has announced great news, and we think it is due to make a move in the near term! Other stocks highlighted include:
V.I.Technologies Inc.(Nasdaq:VITX):Market Perform,
eBay Inc. (Nasdaq:EBAY): Market Underperform,
Universal Express Inc. (OTCBB:USXP): Market Perform,
WHAT THESE RATINGS MEAN:
TheSUBWAY.com ranks stocks from time to time utilizing both fundamental and technical analysis in comparison to the S&P 500 over the short term. These ratings reflect the opinion of TheSUBWAY.com.
ABOUT TheSUBWAY.com:
TheSUBWAY.com, a leader in corporate communications and finance, provides all investors with a wide-ranging set of financial tools, including original stock market commentary, stock quotes, interactive charts, portfolio watch, live chat and message boards, etc., plus the latest news, press releases, investment opinions, and research reports for all companies highlighted on the site. For more daily commentary, go to http://www.thesubway.com/sub_comm.asp." target="_blank" rel="nofollow ugc noopener">http://www.thesubway.com/sub_comm.asp.
All material herein was prepared by Capital Research Group, Inc. (CRG) based upon information believed to be reliable. The information contained herein is not guaranteed by CRG to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. CRG is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.thesubway.com or mentioned herein. CRG has been compensated by third party shareholders or with cash from the company on behalf of one or more of the companies mentioned in this opinion. (CRG has been compensated twenty thousand dollars for rdvn) CRG intends to sell its shares. CRG has sold approximately zero shares to date. CRG may sell its shares for less than the target price given in this opinion. CRG`s affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. CRG will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
SOURCE: Capital Research Group, Inc
INVESTMENT OPINION
VITX -- V.I. Technologies, Inc.
Bis Freitag $1.20 müßten drinsein aufgrund der news von heute 
Vitex Restructures Operations and Reduces Ongoing Expenses
WATERTOWN, Mass., Nov 24, 2003 /PRNewswire-FirstCall via Comtex/ -- V.I. Technologies, Inc. (Nasdaq: VITX) ("Vitex" or "the Company"), a biotechnology company dedicated to developing products that improve the safety of the blood supply by pathogen reduction, today announced a restructuring of operations leading to a significant reduction in ongoing operating expenses. The restructuring comes as a result of the recent decision to halt enrollment in the Phase III chronic trial of the INACTINE(TM) Pathogen Reduction System for red blood cells based on a recommendation from an independent Data Safety Monitoring Committee ("DSMC"). The restructuring includes an immediate reduction in the Company`s headcount by 50% which was put into effect on Friday, November 21. Further spending reductions are being evaluated.
"The decision to halt the chronic study has triggered an intensive review of our spending," said John Barr, President and CEO of Vitex. "Our goal is to reduce our burn rate by approximately 50% from its previous level to approximately $3 million per quarter. This spending would support the ongoing Phase III acute transfusion study in a surgical trial setting while we evaluate the recommendation by the DSMC and work to secure additional funding."
mm
Vitex Restructures Operations and Reduces Ongoing Expenses
WATERTOWN, Mass., Nov 24, 2003 /PRNewswire-FirstCall via Comtex/ -- V.I. Technologies, Inc. (Nasdaq: VITX) ("Vitex" or "the Company"), a biotechnology company dedicated to developing products that improve the safety of the blood supply by pathogen reduction, today announced a restructuring of operations leading to a significant reduction in ongoing operating expenses. The restructuring comes as a result of the recent decision to halt enrollment in the Phase III chronic trial of the INACTINE(TM) Pathogen Reduction System for red blood cells based on a recommendation from an independent Data Safety Monitoring Committee ("DSMC"). The restructuring includes an immediate reduction in the Company`s headcount by 50% which was put into effect on Friday, November 21. Further spending reductions are being evaluated.
"The decision to halt the chronic study has triggered an intensive review of our spending," said John Barr, President and CEO of Vitex. "Our goal is to reduce our burn rate by approximately 50% from its previous level to approximately $3 million per quarter. This spending would support the ongoing Phase III acute transfusion study in a surgical trial setting while we evaluate the recommendation by the DSMC and work to secure additional funding."
mm
liest sich echt ganz gut mm..
mal sehen
akt. 0,69$
bis 1$ sollten die schon laufen
mal sehen
akt. 0,69$
bis 1$ sollten die schon laufen
ASK wird dünner
sieht nicht schlecht aus
akt wird bei 0,69 Luft geholt
sieht nicht schlecht aus
akt wird bei 0,69 Luft geholt
Moin ...
AH gings wieder auf $0.70
Laut Yahoo-Board sind weitere Geldgeber gefunden worden, könnt nen kräftigen rebound bis Freitag geben
Bis 12/2003 kanns gut und gern $1.70 - $2.40 werden
http://finance.messages.yahoo.com/bbs?.mm=FN&action=m&board=…
MM
AH gings wieder auf $0.70
Laut Yahoo-Board sind weitere Geldgeber gefunden worden, könnt nen kräftigen rebound bis Freitag geben
Bis 12/2003 kanns gut und gern $1.70 - $2.40 werden
http://finance.messages.yahoo.com/bbs?.mm=FN&action=m&board=…
MM
Rein was die Erfahrung zeigt wird es jetzt bald wieder stark bergauf gehen!
1,8 Mio gehandelte Stück gestern bei +7,35%
bald wieder bei 1€
bald wieder bei 1€
An der Nasdaq über 10% im Plus
VITX könnte bis 1 Dollar laufen
Aktuell 0,80
In D noch Nachholbedarf
VITX könnte bis 1 Dollar laufen
Aktuell 0,80
In D noch Nachholbedarf
VITX 0,87 +19% an der Nasdaq
In FSE pennt der Makler wohl
In FSE pennt der Makler wohl
0,76€
geduld zahlt sich manchmal eben aus..
(wenn gleich als trading-buy gedacht )
#1 von tdwzb 18.11.03 17:49:20 Beitrag Nr.: 11.367.292 11367292
Dieses Posting: versenden | melden | drucken | Antwort schreiben V.I. TECHNOLOGIES, INC.
VITX - 923144
akt: 0,58€
geduld zahlt sich manchmal eben aus..
(wenn gleich als trading-buy gedacht
)#1 von tdwzb 18.11.03 17:49:20 Beitrag Nr.: 11.367.292 11367292
Dieses Posting: versenden | melden | drucken | Antwort schreiben V.I. TECHNOLOGIES, INC.
VITX - 923144
akt: 0,58€
0,96$
1,03 USD
VK VITX
0,94/0,66
0,94/0,66
siehe #22
........und tut sich hier nochmal was??
hm - könnte nochmal nen rebound geben 
wahrscheinlich aber erst im Januar
wahrscheinlich aber erst im Januar
..hmm danke
@enes
wenn du auf nen rebound spekulierst solltest du dich wahrscheinlich besser
in den nächsten Tagen eindecken
im Jan geht`s dann Richtung Norden
wenn du auf nen rebound spekulierst solltest du dich wahrscheinlich besser
in den nächsten Tagen eindecken
im Jan geht`s dann Richtung Norden
So die gurke hat,
nachdem es sie im november zerrissen hat,
inzwischen wieder einen aufwaertstrend etabliert.
Meint einer es reicht zum gapschluss bei $2.2 oder
wird hier schon beim low von ende oktober bei etwa $1.75
die Luft duenn?
Best
dm
nachdem es sie im november zerrissen hat,
inzwischen wieder einen aufwaertstrend etabliert.
Meint einer es reicht zum gapschluss bei $2.2 oder
wird hier schon beim low von ende oktober bei etwa $1.75
die Luft duenn?
Best
dm
#1 von tdwzb 18.11.03 17:49:20 Beitrag Nr.: 11.367.292 11367292
Dieses Posting: versenden | melden | drucken | Antwort schreiben V.I. TECHNOLOGIES, INC.
VITX - 923144
akt: 0,58€
hatte ich doch glatt das tief erwischt
Dieses Posting: versenden | melden | drucken | Antwort schreiben V.I. TECHNOLOGIES, INC.
VITX - 923144
akt: 0,58€
hatte ich doch glatt das tief erwischt
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 196 | ||
| 93 | ||
| 66 | ||
| 50 | ||
| 46 | ||
| 43 | ||
| 42 | ||
| 37 | ||
| 33 | ||
| 27 |
| Wertpapier | Beiträge | |
|---|---|---|
| 23 | ||
| 21 | ||
| 20 | ||
| 20 | ||
| 20 | ||
| 19 | ||
| 18 | ||
| 18 | ||
| 15 | ||
| 15 |
